SCHEMBL4250144

SCHEMBL4250144

CC(=O)N[C@H](C(=O)O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.52
FPR2 P25090 1/20 0.51
LMNA P02545 2/20 0.50
MAPK1 P28482 1/20 0.50
NAALAD2 Q9Y3Q0 1/20 0.50
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
LTA4H P09960 1/20 0.48
ANPEP P15144 1/20 0.48
ATM Q13315 1/20 0.48
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47
HDAC5 Q9UQL6 1/20 0.47
MTNR1A P48039 1/20 0.47
MTNR1B P49286 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3376625 1.00 SRC (0.52) SRCFPR2LMNAMAPK1NAALAD2
SCHEMBL627377 1.00 SRC (0.52) SRCFPR2LMNAMAPK1NAALAD2
SCHEMBL5936861 0.98 SRC (0.50) SRCFPR2LMNAMAPK1NAALAD2
SCHEMBL14397406 0.88 FPR2 (0.49) SRCFPR2LMNAMAPK1NAALAD2
SCHEMBL5744468 0.88 TACR3 (0.48) SRCMTNR1AMTNR1BALDH1A1KMT2A
SCHEMBL890060 0.88 TACR3 (0.48) SRCMTNR1AMTNR1BALDH1A1KMT2A
SCHEMBL18610229 0.88 TACR3 (0.48) SRCMTNR1AMTNR1BALDH1A1KMT2A
SCHEMBL6970828 0.86 MTNR1A (0.46) SRCMTNR1AMTNR1BALDH1A1KMT2A
SCHEMBL9068474 0.85 HPGD (0.49) SRCFPR2LMNAMAPK1NAALAD2
SCHEMBL14339911 0.85 HPGD (0.49) SRCFPR2LMNAMAPK1NAALAD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090036679-A1 METHOD FOR RESOLVING ENANTIOMERS FROM RACEMIC MIXTURE HAVING CHIRAL CARBON IN ALPHA POSITION OF NITROGEN CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2009-02-05 US claimed
EP-1984358-A1 METHOD FOR RESOLVING ENANTIOMERS FROM RACEMIC MIXTURE HAVING CHIRAL CARBON IN ALPHA POSITION OF NITROGEN Chong Kun Dang Pharmaceutical Corp. (KR) 2008-10-29 EP claimed
WO-2007091753-A1 METHOD FOR RESOLVING ENANTIOMERS FROM RACEMIC MIXTURE HAVING CHIRAL CARBON IN ALPHA POSITION OF NITROGEN CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2007-08-16 WO claimed
US-20230257388-A1 GRANZYME B DIRECTED IMAGING AND THERAPY CYTOSITE BIOPHARMA INC. (US) 2023-08-17 US disclosed
US-11667645-B2 Granzyme B directed imaging and therapy CYTOSITE BIOPHARMA INC. (US) 2023-06-06 US disclosed
WO-2023078410-A1 COMPOUND HAVING ACTIVITY OF DEGRADING GSPT1 AND APPLICATION THEREOF 上海美志医药科技有限公司 2023-05-11 WO disclosed
US-20220266397-A1 FLUX AND SOLDER PASTE KOKI COMPANY LIMITED (JP) 2022-08-25 US disclosed
WO-2021107686-A1 EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF FOR TREATING OR ALLEVIATING NEURODEGENERATIVE OR MOTOR NEURON DISEASES 제이투에이치바이오텍 주식회사 2021-06-03 WO disclosed
CN-112261939-A Granzyme B directed imaging and therapy 塞托赛特生物制药股份有限公司 2021-01-22 CN disclosed
US-20200369673-A1 GRANZYME B DIRECTED IMAGING AND THERAPY CYTOSITE BIOPHARMA INC. 2020-11-26 US disclosed
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 US disclosed
US-7291627-B2 Dihydroimidazo[5.1-a]-beta-carboline derivatives, method for their preparation, and their application as a drug MACEF (FR) 2007-11-06 US disclosed
WO-2007091753-A1 METHOD FOR RESOLVING ENANTIOMERS FROM RACEMIC MIXTURE HAVING CHIRAL CARBON IN ALPHA POSITION OF NITROGEN CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2007-08-16 WO disclosed
US-7217794-B2 Compounds and methods for treatment of thrombosis DAIAMED, INC. (US) 2007-05-15 US disclosed
US-20060089372-A1 Dihydroimidazo[5,1-a]sg(b)-carboline derivatives, method for preparing same and use thereof as medicine MACEF (FR) 2006-04-27 US disclosed
US-5102667-A Antiallergens, antiinflammatory agents, nervous system disorders, immunology, psychological disorders RHONE-POULENC SANTE (FR) 1992-04-07 US disclosed
EP-0163537-A1 1-Propanone derivatives and pharmaceutical compositions containing same TOKYO TANABE COMPANY LIMITED (JP) 1985-12-04 EP disclosed
US-4267174-A AND PROCESS FOR ADMINISTERING BOEHRINGER MANNHEIM, GMBH (DE) 1981-05-12 US disclosed
US-4115439-A Process for the preparation of optically active α-phenylglycine and intermediates thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1978-09-19 US disclosed
US-4107203-A SEED CRYSTALS ADDED TO SOLUTION IN PRESENCE OF METAL CHLORIDE NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1978-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089372-A1 Dihydroimidazo[5,1-a]sg(b)-carboline derivatives, method for preparing same and use thereof as medicine GDI2, GDI1, CYP2A7 SRC 3213/4885FPR2 2038/4885LMNA 3198/4885
US-20230257388-A1 GRANZYME B DIRECTED IMAGING AND THERAPY GZMB, PRF1, CTSB SRC 3760/4885FPR2 452/4885LMNA 783/4885
US-20200369673-A1 GRANZYME B DIRECTED IMAGING AND THERAPY GZMB, PRF1, CTSB SRC 3760/4885FPR2 452/4885LMNA 783/4885
US-20090036679-A1 METHOD FOR RESOLVING ENANTIOMERS FROM RACEMIC MIXTURE HAVING CHIRAL CARBON IN ALPHA POSITION OF NITROGEN SRR, NPEPPS, DNPEP SRC 2827/4885FPR2 2895/4885LMNA 1837/4885
US-11667645-B2 Granzyme B directed imaging and therapy GZMB, PRF1, CTSB SRC 3760/4885FPR2 452/4885LMNA 783/4885
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF BRD4, BRDT, BRD3 SRC 569/4885FPR2 3084/4885LMNA 2473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.